GRAVITY
31.3.2023 04:01:28 CEST | Business Wire | Press release
Gravity (NASDAQ: GRVY), a global game company, released its new 3D platformer game, 'ALTF42', as an Early Access version on Steam on March 31, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230330005345/en/
ALTF42, the permadeath-style 3D platformer sequel to ALTF4, is now available as an Early Access version on Steam starting from March 31 (Graphic: Gravity)
Gravity will take charge of services related to 'ALTF42', a permadeath-style 3D platformer genre game developed by PUMKIM, a Korean game developer, based on the global publishing know-how it has accumulated over the years. ALTF42 is the official follow-up to 'ATLF4' and features an even higher level of difficulty with more dangerous traps than the previous version. The previous one, ALTF4, gained a great popularity from users around the world, topping the list in STOVE review ratings and 70,000 concurrent viewers on Twitch.
As the game is named after the shortcut for forced shutdown, 'ALT+F4', it constantly stimulates the desire to forcefully close the game throughout the play. The game is cleared when the knight character breaks through stages with various traps and reaches a specific destination without losing its life. This game is attracting the attention of many global users due to its insurmountable difficulty in contrast to the simple operation method.
In the Steam Early Access version of ALTF42, although users are only allowed to play certain stages of the game, they can experience most of the core systems. In this version, only two languages, Korean and English, are supported, and game systems such as items, costumes, traps, and supported languages will be gradually supplemented through regular updates.
Yoo Joon, Business Team Leader at Gravity, said, “Gravity is showcasing ALTF42, the official follow-up to ALTF4, which has been loved by many users across the world. I highly recommend trying out the game, as users can experience most of the game’s systems in advance, even in the Early Access version that will be released this time. Starting with ALTF42, we plan to introduce console titles of various genres sequentially, as we have signed global publishing contracts for these titles. We kindly request your continued interest and support.”
More information on ALTF42 Early Access is available at the official Stream website for ALTF42 (https://store.steampowered.com/app/2187230/ALTF42/) and inquiries on game publishing can be made via e-mail (startgravity@gravity.co.kr).
About Gravity
Gravity Co., Ltd is a Korean game company established in April 2000 and a global game company listed on NASDAQ (GRVY). The number of global cumulative accounts of Ragnarok IP, Gravity's representative IP, recorded more than 120 million as of September 30, 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230330005345/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release
Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio
Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building2.9.2026 13:13:00 CEST | Press release
Orascom and Muriya press ahead across Hawana Salalah, Jebel Sifah and the US$90M+ As Sodah Island, signalling long-term conviction in Oman’s future, in step with Vision 2040. Across Oman, Orascom Development and its Sultanate platform, Muriya, are moving forward. While parts of the region grow cautious, Muriya has paused nothing, building and delivering across all three destinations: Hawana Salalah, Jebel Sifah and As Sodah Island. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902781576/en/ Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building (Photo: AETOSWire) The same steadiness runs through everything Samih Sawiris and Orascom have built, from El Gouna to Andermatt to Mamula Island: identifying extraordinary places and developing them for the long term. “Oman has everything we look for as a long-term developer: stability, natural beauty, and a clear direction for its future. Our continued investment
Aukera Closes €460 Million Structured Credit Facility Led by EIG to Support European Energy Infrastructure Portfolio2.9.2026 13:00:00 CEST | Press release
Aukera, the pan-European battery storage and renewable energy platform backed by AtlasInvest, Reggeborgh and SFPIM (Belgium's sovereign wealth fund), announced the closing of its €460 million structured credit facility, for which EIG, a leading institutional investor in the global energy and infrastructure sectors, served as the lead investor. With the financing in place, Aukera moves into its next phase of growth, combining capital, expertise and delivery capability to build a significant European energy infrastructure platform that develops, finances, constructs and operates assets at scale. The original facility included an initial €200 million commitment and an accordion feature of up to €250 million. The amended facility converts that accordion into a firmly committed €260 million Series 2 tranche, increasing total committed capital to €460 million. The additional capital will support the continued advancement of Aukera's portfolio of renewable energy generation, battery storage a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
